Perspective Therapeutics Shares Positive 2026 Trial Update – 43% Response Rate in Advanced Neuroendocrine Tumors
New alpha therapy for advanced NETs shows good safety and early tumor shrinkage in ~43% patients, with encouraging results so far.
/ 1659 items
#XY↓
Barclays Turns Bearish on Janux: Lead Program JANX007 Loses Confidence
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
Barclays Upgrades Celldex to Overweight, Raises Price Target to $45
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
Lilly Buys Kelonia for Up to $7 Billion to Make CAR-T Cancer Therapy Simple and Fast
Eli Lilly buys Kelonia to develop a simpler, one-shot cancer therapy that reprograms immune cells directly inside the body.
UBS Sees 6-9% Growth for Amneal: Why the Recent Dip is a Buying Opportunity
UBS starts coverage on Amneal Pharmaceuticals with a Buy rating. Strong specialty growth, Parkinson’s drugs, and attractive entry point after recent selloff.
Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.